CalciMedica (NASDAQ:CALC – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
CalciMedica Price Performance
Shares of CALC opened at $2.05 on Wednesday. CalciMedica has a 12-month low of $1.83 and a 12-month high of $6.27. The stock has a market capitalization of $27.64 million, a P/E ratio of -1.90 and a beta of 1.20. The firm’s 50 day moving average is $2.45 and its 200-day moving average is $3.20.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a research report on Tuesday, March 4th.
CalciMedica Company Profile
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Stories
- Five stocks we like better than CalciMedica
- How to Calculate Inflation Rate
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to find penny stocks to invest and trade
- NVIDIA Insiders Sell: This Is What It Means for the Market
- How to Use the MarketBeat Stock Screener
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
